Global Tuberculosis Report 2022 (World Health Organization, 2022).
Kislitsyna, N. A. Comparative evaluation of rifampicin and isoniazid penetration into the pathological foci of the lungs in tuberculosis patients. Probl. Tuberk. 4, 55–57 (1985).
Khan, A. et al. Genetic variants and drug efficacy in tuberculosis: a step toward personalized therapy. Glob. Med. Genet. 9, 90–96 (2022).
Tostmann, A. et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J. Gastroenterol. Hepatol. 23, 192–202 (2008).
Mane, S. R. et al. Increased bioavailability of rifampicin from stimuli-responsive smart nano carrier. ACS Appl. Mater. Interfaces 6, 16895–16902 (2014).
Mei, Q. et al. Formulation and in vitro characterization of rifampicin-loaded porous poly (ε-caprolactone) microspheres for sustained skeletal delivery. Drug Des. Devel. Ther. 12, 1533–1544 (2018).
Prabhu, P. et al. Mannose-conjugated chitosan nanoparticles for delivery of rifampicin to osteoarticular tuberculosis. Drug Deliv. Transl. Res. 11, 1509–1519 (2021).
Fenaroli, F. et al. Enhanced permeability and retention-like extravasation of nanoparticles from the vasculature into tuberculosis granulomas in zebrafish and mouse models. ACS Nano 12, 8646–8661 (2018).
Fang, R. H., Kroll, A. V., Gao, W. & Zhang, L. Cell membrane coating nanotechnology. Adv. Mater. 30, e1706759 (2018).
Engering, A. J. et al. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur. J. Immunol. 27, 2417–2425 (1997).
Oldenborg, P. A. et al. Role of CD47 as a marker of self on red blood cells. Science 288, 2051–2054 (2000).
Rodriguez, P. L. et al. Minimal ‘self’ peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339, 971–975 (2013).
Stevens, M. M. & George, J. H. Exploring and engineering the cell surface interface. Science 310, 1135–1138 (2005).
Jafari, A., Nagheli, A., Foumani, A. A., Soltani, B. & Goswami, R. The role of metallic nanoparticles in inhibition of Mycobacterium tuberculosis and enhances phagosome maturation into the infected macrophage. Oman Med. J. 35, e194 (2020).
Maphasa, R. E., Meyer, M. & Dube, A. The macrophage response to Mycobacterium tuberculosis and opportunities for autophagy inducing nanomedicines for tuberculosis therapy. Front. Cell. Infect. Microbiol. 10, 618414 (2020).
Shi, L., Jiang, Q., Bushkin, Y., Subbian, S. & Tyagi, S. Biphasic dynamics of macrophage immunometabolism during Mycobacterium tuberculosis infection. mBio 10, e02550–18 (2019).
Fabriek, B. O. et al. The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. Blood 113, 887–892 (2009).
Matsubara, V. H. et al. Probiotic bacteria alter pattern-recognition receptor expression and cytokine profile in a human macrophage model challenged with Candida albicans and lipopolysaccharide. Front. Microbiol. 8, 2280 (2017).
Nicolaou, G., Goodall, A. H. & Erridge, C. Diverse bacteria promote macrophage foam cell formation via Toll-like receptor-dependent lipid body biosynthesis. J. Atheroscler. Thromb. 19, 137–148 (2012).
Bin, L. et al. Antiviral and anti-inflammatory treatment with multifunctional alveolar macrophage-like nanoparticles in a surrogate mouse model of COVID-19. Adv. Sci. (Weinh.) 8, 2003556 (2021).
Wu, H. H., Zhou, Y., Tabata, Y. & Gao, J. Q. Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic. J. Control. Release 294, 102–113 (2019).
Carlsson, F. et al. Host-detrimental role of Esx-1-mediated inflammasome activation in mycobacterial infection. PLoS Pathog. 6, e1000895 (2010).
Takaki, K., Davis, J. M., Winglee, K. & Ramakrishnan, L. Evaluation of the pathogenesis and treatment of Mycobacterium marinum infection in zebrafish. Nat. Protoc. 8, 1114–1124 (2013).
Kawai, T. & Akira, S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34, 637–650 (2011).
Taylor, P. R. et al. Macrophage receptors and immune recognition. Annu. Rev. Immunol. 23, 901–944 (2005).
Wang, M. et al. A versatile 980 nm absorbing aggregation-induced emission luminogen for NIR-II imaging-guided synergistic photo-immunotherapy against advanced pancreatic cancer. Adv. Funct. Mater. 32, 2205371 (2022).
Tang, M. et al. Near-infrared excited orthogonal emissive upconversion nanoparticles for imaging-guided on-demand therapy. ACS Nano 13, 10405–10418 (2019).
Xu, C., Jiang, Y., Han, Y., Pu, K. & Zhang, R. A polymer multicellular nanoengager for synergistic NIR-II photothermal immunotherapy. Adv. Mater. 33, e2008061 (2021).
Goñi, F. M. The basic structure and dynamics of cell membranes: an update of the Singer–Nicolson model. Biochim. Biophys. Acta Biomembr. 1838, 1467–1476 (2022).
Ramasamy, M., Lee, S. S., Yi, D. K. & Kim, K. Magnetic, optical gold nanorods for recyclable photothermal ablation of bacteria. J. Mater. Chem. B 2, 981–988 (2014).
Yang, Y. et al. Supramolecular radical anions triggered by bacteria in situ for selective photothermal therapy. Angew. Chem. Int. Ed. 56, 16239–16242 (2017).
Zhang, J. et al. Photothermal lysis of pathogenic bacteria by platinum nanodots decorated gold nanorods under near infrared irradiation. J. Hazard. Mater. 342, 121–130 (2018).
Hessel, C. M. et al. Copper selenide nanocrystals for photothermal therapy. Nano Lett. 11, 2560–2566 (2011).
Li, Y. et al. Novel NIR-II organic fluorophores for bioimaging beyond 1550 nm. Chem. Sci. 11, 2621–2626 (2020).
Wang, J. et al. Brain-targeted aggregation-induced-emission nanoparticles with near-infrared imaging at 1550 nm boosts orthotopic glioblastoma theranostics. Adv. Mater. 34, e2106082 (2022).
Liu, S. et al. Incorporation of planar blocks into twisted skeletons: boosting brightness of fluorophores for bioimaging beyond 1500 nanometer. ACS Nano 14, 14228–14239 (2020).
Liu, Y. et al. One-dimensional Fe2P acts as a Fenton agent in response to NIR II light and ultrasound for deep tumor synergetic theranostics. Angew. Chem. Int. Ed. 58, 2407–2412 (2019).
Miao, W. et al. A versatile 980 nm absorbing aggregation-induced emission luminogen for NIR-II imaging-guided synergistic photo-immunotherapy against advanced pancreatic cancer. Adv. Funct. Mater. 32, 2203571 (2022).
Yamamoto, T., Takiwaki, H., Arase, S. & Ohshima, H. Derivation and clinical application of special imaging by means of digital cameras and ImageJ freeware for quantification of erythema and pigmentation. Skin Res. Technol. 14, 26–34 (2008).
Mitteer, D. R., Greer, B. D., Fisher, W. W. & Cohrs, V. L. Teaching behavior technicians to create publication-quality, single-case design graphs in GraphPad prism 7. J. Appl. Behav. Anal. 51, 998–1010 (2018).
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s41565-024-01618-0
